The reported statements, read against the company's own industry.
Financials view
Market Capitalization
212.02MCHF
258.90M · vs all stocks (USD)
Updated Oct 25, 2026
Revenue (TTM)
101.50MCHF
123.95M · vs all stocks (USD)
Updated Oct 25, 2026
Profit Margin
-31.46%
vs Biotechnology peers
Updated Oct 25, 2026
Beta
-0.3930x
vs all stocks
Updated Oct 25, 2026
52-Week Change
30.57%
vs all stocks
Updated Oct 25, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Market Capitalization
212.02MCHF
258.90M · vs all stocks (USD)
Updated Oct 25, 2026
Enterprise Value
207.16MCHF
252.97M · vs all stocks (USD)
Updated Oct 25, 2026
Forward P/E
62.91x
vs Biotechnology peers
Updated Oct 25, 2026
Price to Sales (TTM)
2.09x
vs Biotechnology peers
Updated Oct 25, 2026
Enterprise to Revenue
2.04x
vs Biotechnology peers
Updated Oct 25, 2026
Enterprise to EBITDA
-56.96x
vs Biotechnology peers
Updated Oct 25, 2026
Gross Margin
86.34%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 40.98%.Updated Oct 25, 2026
Profit Margin
-31.46%
vs Biotechnology peers
Updated Oct 25, 2026
Operating Margin
-13.58%
vs Biotechnology peers
Updated Oct 25, 2026
Return on Assets (TTM)
-3.93%
vs Biotechnology peers
Updated Oct 25, 2026
Revenue (TTM)
101.50MCHF
123.95M · vs all stocks (USD)
Updated Oct 25, 2026
Revenue per Share (TTM)
7.36CHFUpdated Oct 25, 2026
Quarterly Revenue Growth
101.30%
vs Biotechnology peers
Updated Oct 25, 2026
Gross Profit (TTM)
41.60MCHF
50.80M · vs all stocks (USD)
Updated Oct 25, 2026
EBITDA (TTM)
-3.64MCHF
-4.44M · vs all stocks (USD)
Updated Oct 25, 2026
Net Income (TTM)
-31.93MCHF
-38.99M · vs all stocks (USD)
Updated Oct 25, 2026
Operating Cash Flow (TTM)
660.00KCHF
805.95K · vs all stocks (USD)
Updated Oct 25, 2026
Levered Free Cash Flow (TTM)
-21.16MCHF
-25.84M · vs all stocks (USD)
Updated Oct 25, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Trailing Annual Dividend Rate
0.00CHFUpdated Oct 25, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 25, 2026
Revenue
77.19MCHFFY2025 · Dec 31, 2025
Cost of Goods Sold
62.01MCHFFY2025 · Dec 31, 2025
Gross Profit
15.17MCHFFY2025 · Dec 31, 2025
Operating Income
-37.61MCHF
-45.93M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-49.05MCHFFY2025 · Dec 31, 2025
Income Tax Expense
185.00KCHFFY2025 · Dec 31, 2025
Net Income
-49.24MCHFFY2025 · Dec 31, 2025
EBIT
-37.49MCHFFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-35.05MCHFFY2025 · Dec 31, 2025
Research & Development
22.22MCHFFY2025 · Dec 31, 2025
Selling, General & Administrative
30.77MCHFFY2025 · Dec 31, 2025
Non-operating Interest Income
409.00KCHFFY2025 · Dec 31, 2025
Non-operating Interest Expense
11.56MCHFFY2025 · Dec 31, 2025
EPS (Basic)
-3.78CHFFY2025 · Dec 31, 2025
EPS (Diluted)
-3.78CHFFY2025 · Dec 31, 2025
Basic Shares Outstanding
13.01MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
13.01MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-49.05MCHFFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CHFFY2025 · Dec 31, 2025
Operating Cash Flow
-34.91MCHFFY2025 · Dec 31, 2025
Free Cash Flow
-34.96MCHFFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
22.44MCHFFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-49.05MCHFFY2025 · Dec 31, 2025
Stock-based Compensation
4.25MCHFFY2025 · Dec 31, 2025
Other Non-cash Items
11.21MCHFFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-1.31MCHFFY2025 · Dec 31, 2025
Capital Expenditures
-52.00KCHFFY2025 · Dec 31, 2025
Purchase of Investments
-70.00KCHFFY2025 · Dec 31, 2025
Sale of Investments
0.00CHFFY2025 · Dec 31, 2025
Net Investing Cash Flow
-122.00KCHFFY2025 · Dec 31, 2025
Long-term Debt Issuance
9.69MCHFFY2025 · Dec 31, 2025
Long-term Debt Payments
0.00CHFFY2025 · Dec 31, 2025
Other Financing Charges
6.86MCHFFY2025 · Dec 31, 2025
Net Financing Cash Flow
17.21MCHFFY2025 · Dec 31, 2025
Shares Outstanding
13.39MSharesUpdated Oct 25, 2026
Float Shares
12.63MSharesUpdated Oct 25, 2026
% Held by Insiders
11.15%
vs all stocks
Updated Oct 25, 2026
% Held by Institutions
16.58%
vs all stocks
Updated Oct 25, 2026
Total Cash (MRQ)
41.77MCHF
51.01M · vs all stocks (USD)
Updated Oct 25, 2026
Total Cash per Share (MRQ)
2.78CHFUpdated Oct 25, 2026
Total Debt (MRQ)
41.27MCHF
50.40M · vs all stocks (USD)
Updated Oct 25, 2026
Current Ratio (MRQ)
1.73x
vs Biotechnology peers
Updated Oct 25, 2026
Book Value per Share (MRQ)
-0.4110CHFUpdated Oct 25, 2026
Total Assets
148.09MCHF
180.83M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
80.24MCHFFY2025 · Dec 31, 2025
Total Liabilities
159.90MCHFFY2025 · Dec 31, 2025
Total Non-current Assets
67.84MCHFFY2025 · Dec 31, 2025
Total Non-current Liabilities
97.73MCHFFY2025 · Dec 31, 2025
Total Current Liabilities
62.17MCHFFY2025 · Dec 31, 2025
Cash
22.44MCHFFY2025 · Dec 31, 2025
Cash Equivalents
0.00CHFFY2025 · Dec 31, 2025
Cash & Cash Equivalents
22.44MCHFFY2025 · Dec 31, 2025
Accounts Receivable
8.70MCHFFY2025 · Dec 31, 2025
Inventory
24.87MCHFFY2025 · Dec 31, 2025
Accounts Payable
13.58MCHFFY2025 · Dec 31, 2025
Short-term Debt
14.85MCHFFY2025 · Dec 31, 2025
Other Current Liabilities
7.15MCHFFY2025 · Dec 31, 2025
Long-term Debt
34.10MCHFFY2025 · Dec 31, 2025
Other Non-current Liabilities
39.93MCHFFY2025 · Dec 31, 2025
Common Stock (Book)
1.40MCHFFY2025 · Dec 31, 2025
Retained Earnings
-663.93MCHFFY2025 · Dec 31, 2025
Total Shareholders' Equity
-11.82MCHF
-14.43M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
62.00KCHFFY2025 · Dec 31, 2025
52-Week Low
10.06CHFUpdated Oct 25, 2026
52-Week High
18.84CHFUpdated Oct 25, 2026
52-Week Change
30.57%
vs all stocks
Updated Oct 25, 2026
Beta
-0.3930x
vs all stocks
Updated Oct 25, 2026
50-Day MA
15.34CHFUpdated Oct 25, 2026
200-Day MA
15.51CHFUpdated Oct 25, 2026
Avg 10-Day Volume
45.86KSharesUpdated Oct 25, 2026
Avg 30-Day Volume
60.11KSharesUpdated Oct 25, 2026
Diluted EPS (TTM)
-2.19CHFUpdated Oct 25, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.86Profit Margin: -0.31
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $258.9M, lower than 95% of all stocks globallySignificant
Market cap (USD): 258,904,341.916Global P5: 273,689,256.68
Companies that share the same coordination system — how they create, deliver, or capture value.